Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands

BACKGROUND: Cladribine tablets have recently become available in The Netherlands for patients with relapsing–remitting multiple sclerosis (RRMS) as a disease-modifying agent that reduces the frequency and severity of relapses and delays disability progression. OBJECTIVE: The aim of this study was to...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Appl Health Econ Health Policy
Autors principals: Michels, Renée Else, de Fransesco, Maria, Mahajan, Koshu, Hengstman, Gerald J. D., Schiffers, Krijn M. H., Budhia, Sangeeta, Harty, Gerard, Krol, Marieke
Format: Artigo
Idioma:Inglês
Publicat: Springer International Publishing 2019
Matèries:
Original Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6885501/
https://ncbi.nlm.nih.gov/pubmed/31444659
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40258-019-00500-8
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars